Skip to content

    Sexual Health Center

    Font Size
    A
    A
    A

    'Female Viagra' Is Rejected by FDA Panel

    Advisory Committee Opposes Approval of Filbanserin to Treat Low Sexual Desire in Women
    By
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    June 18, 2010 -- An FDA advisory panel unanimously rejected what some had hoped would become the first drug approved to boost sexual desire in women.

    Experts said the drug, widely dubbed "female Viagra," showed little evidence of working and raised safety concerns. If the FDA follows the recommendation of the advisory panel, it would send drugmakers back to the lab in their quest to come up with a drug that could be marketed to women with lower-than-desired libidos.

    German drugmaker Boehringer Ingelheim had hoped to sell the drug, known as flibanserin, as the first medication targeting low sexual desire in premenopausal women. They pointed to studies showing that women who took the drug reported slightly increased feelings of sexual desire and more satisfying sexual episodes than women who took a placebo.

    But experts were unconvinced that the increases were clinically meaningful.

    "This is not an effective drug," said Bryce Reeve, PhD, program director of the Outcomes Research Branch at the National Cancer Institute and a member of the advisory committee.

    Experts were also troubled that the company abandoned part way through its study the scale it used to measure women's experience after less than promising results.

    "This would be highly inappropriate," said Scott Emerson, MD, a professor of biostatistics at the University of Washington and a member of the advisory panel.

    Flibanserin has been widely touted as the "female Viagra," though the moniker is not quite accurate. Unlike male erectile dysfunction drugs, which are taken minutes or hours before desired sexual activity, flibanserin is taken once a day. And while Viagra and similar drugs work directly on the physiology of the penis and do not increase actual sexual desire, flibanserin acts on the central nervous system, presumably in the pleasure centers of the brain.

    Still, that has not stopped drugmakers from pursuing Viagra-like blockbuster status for a similar drug for women. In this case, Boehringer Ingelheim wanted to sell flibanserin to treat hyposexual desire disorder, or HSDD.

    Debate Over Hyposexual Desire Disorder

    Estimates suggest more than 6% of women between 30 and 39 years of age have HSDD. Numbers climb as women age and reach menopause.

    Today on WebMD

    Sex Drive Killers Slideshow
    Slideshow
    How Healthy is Your Sex Life
    Quiz
     
    HPV Vaccine Future
    Article
    Couple in bed
    Video
     
    HIV Myth Facts
    Slideshow
    STD Overview
    Slideshow
     
    Birth control pills
    Slideshow
    Herpes Vaccine Study
    Video
     
    6 Tips For Teens
    Feature
    things your guy wish you knew slideshow
    Slideshow
     
    Tense teen couple
    Article
    Better Sex Exercises
    Article